Myriad Genetics Signs Marketing Plans With Pfizer For BRACAnalysis CDx Test

09 Oct 2018

Myriad Genetics, Inc. and Pfizer Inc. signed an agreement to promote Myriad's BRACAnalysis CDx test, currently under US FDA review, as a companion diagnostic for Pfizer's investigational breast cancer drug, talazoparib.

Myriad Genetics Inc. inked a deal with pharmaceutical giant Pfizer Inc. to promote Myriad's BRACAnalysis CDx test to identify breast cancer patients that would benefit from treatment with talazoparib, Pfizer's investigational poly-ADP ribose polymerase inhibitor drug.

Under the agreement, both companies will remain responsible for marketing their own products, but will collaborate on certain activities to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

12 Jun 2025

• By Natasha Barrow

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

29 May 2025

• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.